ARDS insider filings
Aridis Pharmaceuticals, Inc. — 39 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-06-28. Screen ARDS transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for ARDS between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Aridis Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-06-28 | 4 | Windham-Bannister Susan Richards — Director | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Jafri Hasan — Chief Medical Officer | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Patzer Eric — Director | Purchase (P): 714,286 @ $0.07 | EDGAR |
| 2024-06-28 | 4 | Truong Vu — CEO, Director | Purchase (P): 714,286 @ $0.07 | EDGAR |
| 2024-06-28 | 4 | HAMILTON JOHN F — Director | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-09-19 | 4 | Jafri Hasan — Chief Medical Officer | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-09-19 | 4 | Windham-Bannister Susan Richards — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-09-19 | 4 | Patzer Eric — Executive Chairman, Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-09-19 | 4 | Truong Vu — CEO and Director, Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-09-19 | 4 | HAMILTON JOHN F — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Patzer Eric — Executive Chairman, Director | Option exercise (M): 12,000 · Grant/award (A): 30,000 (derivative) @ $0 · Option exercise (M): 12,000 (derivative) | EDGAR |
| 2023-06-15 | 4 | Truong Vu — CEO and Director, Director | Option exercise (M): 15,000 · Grant/award (A): 100,000 (derivative) @ $0 · Option exercise (M): 15,000 (derivative) | EDGAR |
| 2023-06-15 | 4 | Windham-Bannister Susan Richards — Director | Option exercise (M): 5,000 · Grant/award (A): 15,000 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) | EDGAR |
| 2023-06-15 | 4 | Jafri Hasan — Chief Medical Officer | Option exercise (M): 10,000 · Grant/award (A): 25,000 (derivative) @ $0 · Option exercise (M): 10,000 (derivative) | EDGAR |
| 2023-06-15 | 4 | KURLAND FRED — CFO | Option exercise (M): 4,000 · Grant/award (A): 10,000 (derivative) @ $0 · Option exercise (M): 4,000 (derivative) | EDGAR |
| 2023-06-15 | 4 | HAMILTON JOHN F — Director | Option exercise (M): 5,000 · Grant/award (A): 15,000 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) | EDGAR |
| 2022-12-07 | 4 | Truong Vu — Chief Executive Officer, Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-12-07 | 4 | Patzer Eric — Executive Chairman, Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2022-12-07 | 4 | Jafri Hasan — Chief Medical Officer | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-12-07 | 4 | Gibbs Craig S — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-12-07 | 4 | Windham-Bannister Susan Richards — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-12-07 | 4 | KURLAND FRED — Chief Financial Officer | Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2022-12-07 | 4 | HAMILTON JOHN F — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-12-07 | 4 | RUFFOLO ROBERT R — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-06-08 | 4 | Truong Vu — CEO and Director, Director | Grant/award (A): 88,360 (derivative) @ $0 | EDGAR |
| 2021-10-05 | 4 | Windham-Bannister Susan Richards — Director | Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2021-10-05 | 4 | Jafri Hasan — Chief Medical Officer | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2021-10-05 | 4 | Gibbs Craig S — Director | Grant/award (A): 7,900 (derivative) @ $0 | EDGAR |
| 2021-10-05 | 4 | KURLAND FRED — CFO | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-10-05 | 4 | HAMILTON JOHN F — Director | Grant/award (A): 9,400 (derivative) @ $0 | EDGAR |
| 2021-10-05 | 4 | RUFFOLO ROBERT R — Director | Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2021-09-08 | 4 | Jafri Hasan — Chief Medical Officer | Purchase (P): 3,009 @ $4.15 · Purchase (P): 1,991 @ $4.15 · Purchase (P): 100 @ $3.97 | EDGAR |
| 2021-07-27 | 4 | Truong Vu — CEO, Director | Purchase (P): 5,000 @ $5.11 | EDGAR |
| 2021-07-27 | 4 | Patzer Eric — Director | Purchase (P): 5,175 @ $4.84 | EDGAR |
| 2021-07-27 | 4 | HAMILTON JOHN F — Director | Purchase (P): 2,000 @ $4.87 | EDGAR |
| 2021-05-13 | 4 | Truong Vu — CEO and Director, Director | Grant/award (A): 53,340 (derivative) @ $0 | EDGAR |
| 2021-04-02 | 4 | Jafri Hasan — Chief Medical Officer | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-02-22 | 4 | Nazak Michael Adrian — Chief Financial Officer | Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2021-02-18 | 4 | Patzer Eric — Chairman, Director, 10% owner | Gift (G): 16,000 @ $0 | EDGAR |
Recent 8-K events — Aridis Pharmaceuticals, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-06-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-01-16 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2023-12-18 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-11-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-09-07 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2023-08-25 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2023-08-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-07-20 | 8-K | 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement | EDGAR |
| 2023-07-18 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2023-06-23 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ARDS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs